Postoperative hepatitis - Biotech, Pharma and Life Science Channel

20:42 EDT 22nd October 2014 | BioPortfolio

PubMed Articles [3728 Associated PubMed Articles listed on BioPortfolio]

Simeprevir (Olysio) for chronic hepatitis c.

Hepatitis B in Pregnancy.

Hepatitis B Virus (HBV) infects over 2 billion people worldwide, with approximately 360 million chronically infected. It results in substantial morbidity and mortality, with an estimated 600,000 death...

Treatment options beyond IFNα and NUCs for chronic HBV infection: expectations for tomorrow.

Chronic hepatitis B virus (HBV) infection may progress to cirrhosis, hepatocellular carcinoma (HCC) and end-stage liver failure with time. Interruption of this process can only be achieved through eff...

B-type natriuretic peptide following thoracic surgery: a predictor of postoperative cardiopulmonary complications†.

B-type natriuretic peptides (BNPs) are secreted by the human heart in response to ventricular wall stretch or myocardial ischaemia, and predict adverse cardiovascular events and death in the general p...

Association of Chronic Hepatitis C Infection With T-Cell Phenotypes in HIV-Negative and HIV-Positive Women.

Hepatitis C virus (HCV) viremia is thought to have broad systemic effects on the cellular immune system that go beyond its impact on just those T cells that are HCV specific. However, previous studies...

Postdischarge Occurrences After Colorectal Surgery Happen Early and Are Associated With Dramatically Increased Rates of Readmission.

Postoperative occurrences have been associated with an increased risk of readmission, yet these occurrences and their timing have not been well characterized.

The Effect of Transversus Abdominis Plane Blocks on Postoperative Pain in Laparoscopic Colorectal Surgery: A Prospective, Randomized, Double-Blind Trial.

Superior early pain control has been suggested with transversus abdominis plane blocks, but evidence-based recommendations for transversus abdominis plane blocks and their effects on patient outcomes ...

Relationship between deep venous thrombosis and inflammatory cytokines in postoperative patients with malignant abdominal tumors.

Deep venous thrombosis (DVT) is a common surgical complication in cancer patients and evidence that inflammation plays a role in the occurrence of DVT is increasing. We studied a population of cancer ...

Occult hepatitis B virus infection in liver transplant patients in a Brazilian referral center.

Estimates of occult hepatitis B virus (HBV) infection prevalence varies among different studies depending on the prevalence of HBV infection in the study population and on the sensitivity of the assay...

Antimicrobial Effect of Continuous Lidocaine Infusion in a Staphylococcus aureus-Induced Wound Infection in a Mouse Model.

Continuous infusion of local anesthetics in surgical wounds has been shown to be an effective technique for postoperative analgesia. To investigate the potential antimicrobial effect of continuous loc...

News Articles [1317 Associated News Articles listed on BioPortfolio]

Harvoni® (ledipasvir/sofosbuvir) approved for the treatment of chronic hepatitis C, genotype 1 infection in adults; Diplomat to distribute

FLINT, Mich., Oct. 22, 2014 /PRNewswire/ -- U.S. Food and Drug Administration (FDA) announced October 10, 2014 that Gilead Sciences Harvoni® (ledipasvir/sofosbuvir) product was approved for the t...

Regulus Therapeutics, Inc. Gets Seat At Hepatitis C Table With Impressive Phase 1 Results; Stock Up 99.98% At 12:54PM ET On Wednesday

Harvoni will keep Gilead atop Hepatitis C virus treatment landscape, says GlobalData Analyst

The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) i...

The 65th Annual Meeting of the American Association for the Study of Liver Diseases

ALEXANDRIA, Va. and BOSTON, Oct. 22, 2014 /PRNewswire/ -- The Liver Meeting® is the premier Annual Meeting in the science and practice of hepatology, including the latest findings on new dru...

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human p...

Treating hepatitis C with Sovaldi: Is it worth it?

One catch phrase in health care reform is cost-effectiveness.  To paraphrase, this label means that a medical treatment is worth the price.  For example, influenza vaccine, or flu shot, is effective...

Hepatera and MYR plan hepatitis D-Day

Private Russian biotech company Hepatera and its German development partner MYR have early data suggesting that their entry inhibitor Myrcludex B may be an option for treating hepatitis delta, as well...

Giving pricey hepatitis drug to prisoners may be financially wise

NEW YORK (Reuters Health) - When prisoners have hepatitis C, treating them with expensive new antiviral drugs makes fiscal sense despite the hefty price tag, according to a new study.

Enanta declines option on AbbVie-partnered hepatitis C candidate

Enanta also says that it has reached a new agreement with AbbVie regarding royalty calculations for ABT-450-containing regimens, as well as any regimens containing ABT-493. As per their 2006 agreement...

Hepatitis: Exosomal route of HCV transmission exists in patients

Events [0 Results]

None

Companies [26 Associated Companies listed on BioPortfolio]

Vaxart, Inc.

Vaxart is a privately owned company developing oral recombinant vaccines based on its proprietary delivery platform. The Vaxart platform is suitable to deliver any protein vaccine...

Advanced Biological Laboratories

Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc...

Ichor Medical Systems, Inc.

Ichor Medical Systems’ TriGrid™ Delivery System (TriGrid) is the first integrated and fully automated device for electroporation-mediated DNA administration in humans. I...

Transgene SA

Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a biopharmaceutical company. It creates, develops and manufactures targeted immunotherapeutics for th...

AbbVie

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the exp...

Okairos

Okairos is a clinical-stage biopharmaceutical company, developing genetic vaccines for major infectious diseases - including malaria, hepatitis C, influenza, respiratory syncytial...

Profectus BioSciences, Inc.

Profectus BioSciences, Inc. is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases with a goal of reducing morbidity and mo...

Viropro

Viropro Inc. (“Viropro”) operates through Viropro International Inc., a Canadian company with its Head Office in Montreal. Viropro International Inc. is specialized in the technology transfer, fo...

Enanta Pharmaceuticals, Inc.

Enanta Phatmaceuticals ARE A RESEARCH AND DEVELOPMENT-FOCUSED BIOTECHNOLOGY COMPANY that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in t...

Emergent BioSolutions

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission—to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therape...

Clinical Trials [1835 Associated Clinical Trials listed on BioPortfolio]

A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182)

The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following dental surgery.

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

The substances BI 201335 and BI 207127 are being developed for the treatment of chronic hepatitis C virus infection. BI 201335 and BI 207127 work by preventing the virus from replicating. ...

Suture vs Staples for Skin Closure After Liver Resection

Closure of the skin after liver resection (surgery to remove part of the liver) may be achieved by one of several methods. The standard method at our institution is to use stainless steel ...

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) G

To demonstrate the effectiveness of DCV 3DAA fixed dose regimen in treatment naive and treatment experienced non-cirrhotic subjects

Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Naive CHB Patients in China

To compare the effectiveness, in a real world practice setting in tier 2 cities of China, of Entecavir (ETV) monotherapy and Lamivudine (LAM) based therapies (including LAM monotherapy, de...

A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

The primary objective of this program is to provide Daclatasvir (DCV) for 24 weeks to be given in combination with Sofosbuvir (SOF) to post-liver transplant subjects with chronic hepatit...

A Study Comparing Continuous Sciatic Nerve Block to Single Shot Sciatic Nerve Block

The purpose of this study is to compare the incidence of postoperative symptoms of neurologic injury after a single shot infragluteal-parabiceps sciatic nerve block versus a continuous inf...

A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.

This 7 arm study will determine the optimal treatment combination, based on effi cacy and safety. Patients with chronic hepatitis C (CHC), genotype 1, will be ra ndomized to one of 7 treat...

Corneal Power, Astigmatism, and Aberration Changes After LASIK

The primary goal of the study is to determine if Optical Coherence Tomography (OCT) measurement of corneal power and astigmatism is more accurate than conventional Placido-ring corneal top...

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

This single arm study will evaluate the efficacy and safety of PEGASYS (180 micr ograms sc weekly) plus ribavirin (1000-1200mg po daily) in treatment-naive Latin o patients versus non-Lat...

Medical and Biotech [MESH] Definitions

INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).

A family of hepatotropic DNA viruses which contains double-stranded DNA genomes and causes hepatitis in humans and animals. There are two genera: AVIHEPADNAVIRUS and ORTHOHEPADNAVIRUS. Hepadnaviruses include HEPATITIS B VIRUS, duck hepatitis B virus (HEPATITIS B VIRUS, DUCK), heron hepatitis B virus, ground squirrel hepatitis virus, and woodchuck hepatitis B virus (HEPATITIS B VIRUS, WOODCHUCK).

A species in the genus HEPATOVIRUS containing one serotype and two strains: HUMAN HEPATITIS A VIRUS and Simian hepatitis A virus causing hepatitis in humans (HEPATITIS A) and primates, respectively.

INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.

INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.

Search BioPortfolio:
Loading
Advertisement
Advertisement
review and buy Postoperative hepatitis market research data and corporate reports here

Channels Quicklinks